Our laboratory in the School of Medicine at The Johns Hopkins University in Baltimore Maryland investigates the mechanisms of neurodegeneration in neurologic disease, including amyotrophic lateral sclerosis (ALS), Huntington's disease, and Alzheimer's disease. We have several recent high profile papers in Nature, Cell, and Neuron delineating the importance of dysfunctional nucleocytoplasmic transport in these diseases. We are also very interested specifically in the contribution of oligodendrocyte dysfunction in ALS to neuron degeneration. We have published previously in Nature, Nature Neuroscience, and Neuron on the role of oligodendrocytes in supporting axons in healthy brains and ALS patients, and demonstrating the early and profound loss of oligodendrocytes in ALS animal models. Current research in the laboratory is focused on further defining the specific nature of this transport deficit in C9orf72 ALS, which is the most common inherited form of the disease, and devising therapies to selectively correct this defect. Our laboratory is also interested in the distribution of specific nuclear pore proteins in different brain cells, including neurons, astrocytes, and oligodendrocytes, and how these nuclear pore proteins contribute to cellular function in health and disease. Finally, we are interested specifically in the contribution of oligodendrocytes to neurodegeneration in C9orf72 ALS, and whether altered nucleocytoplasmic transport contributes to the observed oligodendrocyte degeneration and dysfunction in this disease.
We are seeking highly motivated individuals with a background in cell or molecular biology to apply for a Post-Doctoral Research Fellowship in the laboratories of Drs. Jeffrey Rothstein and Brett Morrison at The Johns Hopkins University in Baltimore Maryland. Our laboratories investigate the cell-specific mechanisms of degeneration in neurologic diseases, including amyotrophic lateral sclerosis (ALS), Huntington's disease, Alzheimer's disease, and peripheral neuropathy. We are looking for a Post-Doctoral Research Fellow to join our group studying the role of nuclear pores in the normal function of oligodendrocyte-lineage cells and the contribution of dysfunctional nuclear pores to oligodendrocyte degeneration and dysfunction in ALS. Our laboratory has extensive experience in both nuclear pore and oligodendrocyte biology and are looking for individuals interested in gaining experience in this exciting, fast-moving field of study.
Applicants should have 1) earned or close to finishing a Ph.D.; 2) experience in neuroscience, cell biology, or molecular biology; and 3) an interest in neurodegenerative diseases. Ideal applicants would have experience with oligodendrocyte-lineage cells, animal models, and cell cultures. We are looking to fill this position as soon as possible, but would certainly be willing to wait for the perfect candidate.
1) Earned or close to finishing a Ph.D.; 2) Experience in neuroscience, cell biology, or molecular biology; and 3) An interest in neurodegenerative diseases.
Education: Ph.D. (completed or close to completing)
Internal Number: 1
About Johns Hopkins University
Jeffrey D. Rothstein, M.D., Ph.D. is the John W. Griffin Director for the Brain Science Institute, as well as a Professor of Neurology and Neuroscience, and the Founding Director of the Robert Packard Center for ALS Research at Johns Hopkins University School of Medicine. He received his BA in Neuroscience from Colgate University (1977), along with an MA in Neurochemistry-Biopsychology from the University of Chicago (1979). He received his PhD in Physiology and Biophysics-Neurochemistry (1984), and MD (1985) at the University of Illinois College of Medicine and Health Sciences Center. He completed a medical University of North Carolina , Chapel Hill and his neurology residency (1989) and neuromuscular fellowship (1991) at Johns Hopkins University. In 1991, Dr. Rothstein accepted a position as Assistant Professor in the Department of Neurology. In 2000, in addition to being promoted to his current position as Professor of Neurology and Neuroscience, Dr. Rothstein became the Director and Founder of the Robert Packard Center for ALS Research, which has raised approximately $130 million to date. In 2011, he became the Director of the Johns Hopkins Brain Science Institute; a University ...Wide Translational Neuroscience institute founded on a $100mil gift. A respected and internationally renowned neuroscientist, Dr. Rothstein is credited as being one of the world’s top clinical and basic ALS researcher and has over 30 years as a clinician scientist studying ALS pathophysiology, astrocyte/oliogodendroglial biology and therapy discovery; it was his research on ALS pathogenesis that lead to the first successful, FDA-approved drug to alter neurodegeneration in ALS. More recently his group has defined the basic cellular defect in nuclear transport/pores that underlie a large percentage of ALS, Huntington’s disease and Alzheimer’s dementia patients. He holds patents for candidate therapeutics and started a biotech company to help develop drugs and PET ligands for neurodegeneration. In addition to running an ALS clinic at Johns Hopkins which evaluates and manages over 400 ALS patients every year, he also runs a Brain Science Institute drug discovery group to identify novel therapeutics for neurological and psychiatric disease. Dr. Rothstein has received numerous awards for his work in the field of ALS and basic-to-clinical science, such as the Sheila Essay Award recognizing his worldwide contribution to ALS research, and the Diamond Award for ALS research, as well as the Lois Pope Foundation award for medical research, the Swiss Hartmann Muller Prize and more.